| __timestamp | Corcept Therapeutics Incorporated | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 5078000000 |
| Thursday, January 1, 2015 | 36949000 | 4717000000 |
| Friday, January 1, 2016 | 45240000 | 5096000000 |
| Sunday, January 1, 2017 | 62416000 | 4986000000 |
| Monday, January 1, 2018 | 81289000 | 4214000000 |
| Tuesday, January 1, 2019 | 100359000 | 3806000000 |
| Wednesday, January 1, 2020 | 105326000 | 3671000000 |
| Friday, January 1, 2021 | 122356000 | 3528000000 |
| Saturday, January 1, 2022 | 152848000 | 3445000000 |
| Sunday, January 1, 2023 | 184259000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Corcept Therapeutics Incorporated from 2014 to 2023.
Teva, a global leader, saw its SG&A expenses peak in 2014, with a gradual decline of approximately 31% by 2023. This trend reflects Teva's strategic cost-cutting measures amidst industry challenges.
Conversely, Corcept's SG&A expenses surged by over 400% during the same period, highlighting its aggressive expansion and investment in growth. This increase underscores Corcept's commitment to innovation and market penetration.
These contrasting trends offer a glimpse into the strategic priorities of these pharmaceutical giants, providing valuable insights for investors and industry analysts alike.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights